Company intelligence / Profile preview

Innospera Pharma Inc.

Ownership: Private
Development stage: Preclinical

Overview

Innospera’s lead drug candidate, ING‑006, targets IPF and has demonstrated superior potency to existing products in preclinical models. The company is preparing for clinical development and claims its approach offers an exceptional balance of safety and efficacy in targeting inflammatory and metabolic pathways. No human trial results have been reported yet.

Therapeutic areas: PulmonologyMetabolic Disorders
Modalities: Small moleculesSmall molecule GPCR modulators
Industry: Biotech

Drug pipeline

2 assets

ING-006

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Investissement Québec, Seido Capital, Anges Québec provided $5M seed financing in May 2025

Beyond the preview

Go deeper on Innospera Pharma Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innospera Pharma Inc..

Explore the full profile